12:00 AM
May 28, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Dulaglutide: Phase II data

Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind.
Product: Dulaglutide ( GLP-1Fc) ( LY2189265)
Business: Endocrine/Metabolic
Molecular target: Glucagon-like peptide-1 (GLP-1)
Description: Long-acting glucagon-like peptide-1 (GLP-1) receptor agonist
Indication: Treat Type II diabetes
Endpoint: Change from baseline in mean 24-hour systolic blood pressure (SBP) as measured by ambulatory blood pressure monitoring (ABPM) at week 16; mean 24-hour diastolic blood pressure (DBP) and mean 24-hour heart rate
Status: Phase II data...

Read the full 355 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >